中国首个自主研发的肺癌MET靶向药获批上市 - 2021年06月30日

A domestically developed drug targeting one type of lung cancer was approved by the national authority, the first in the world tailored to the specific genetic mutation it targets.

Savolitinib specifically targets lung cancer with MET exon 14 skipping mutation, found in 2 to 3 percent of lung cancer patients, which translates to 8,000 new cases in China every year.

Previously, there was no effective medication to treat the mutation, and the average survival rate is only six to eight months with ordinary chemotherapy.